Efficacy of Gonadotropin-Releasing Hormone Agonist and an Extended-Interval Dosing Regimen in the Treatment of Patients with Adenomyosis and Endometriosis

Kang JL, Jia-li Kang, Wang XX, Xiao-xia Wang, Xiaoxia Wang, Nie ML, Miao-ling Nie, Xiao-hui Huang, Huang XH
Gynecologic and obstetric investigation · 2009 · vol. 69(2) , pp. 73–77 · doi:10.1159/000258683 · PMID:19923847 · W2093554208
article OA: closed CC0 ⤵ 27 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This prospective study found that an extended-interval GnRH-a dosing regimen similarly reduced uterine volume and achieved hypoestrogenism compared to conventional dosing in patients with adenomyosis and endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

AIMS: To determine the effects of gonadotropin-releasing hormone agonist (GnRH-a) and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. METHODS: This was a prospective observational study in the setting of a hospital outpatient clinic. Seventy women suffering from adenomyosis and endometriosis were randomly divided into 2 groups: extended-interval dosing (experimental group) and conventional dosing (control group). METHODS: Patients in the experimental group received a 4-dose regimen (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses). The patients in the control group received a conventional regimen (1 injection every 4 weeks for a total of 6 doses). The main outcome measures were relief and recurrence of dysmenorrhea and related climacteric symptoms, reduction of uterine volume, and serum levels of 17-beta-oestradiol (E(2)), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). RESULTS: The reliving rate of dysmenorrhea was 100% in patients treated with both the new regimen and the convention regimen after 6 months. The uterine volume was reduced 37.6% and 39.2%, respectively. And the levels of LH, FSH and E(2) were decreased significantly (p 0.05). CONCLUSION: The use of the extended-interval dosing regimen of triptorelin depot in patients with adenomyosis or endometriosis results in a consistent hypo-oestrogenised state, which is similar to that achieved by the conventional regimen. The new regimen reduces the cost of treatment.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosisadenomyosis

MeSH descriptors

Dysmenorrhea Endometriosis Gonadotropin-Releasing Hormone Triptorelin Pamoate Adult Delayed-Action Preparations Drug Administration Schedule Dysmenorrhea Dysmenorrhea Endometriosis Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Gonadotropin-Releasing Hormone Humans Injections, Intramuscular Luteinizing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (7)

Cited by (28)

Source provenance

europepmc
last seen: 2026-08-04T06:16:37.499272+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:53.633898+00:00
License: CC0 · commercial use OK